Advanced Therapies Development To Be Accelerated By New UK Alliance

UK alliance to accelerate development of advanced therapies

The University College London has joined forces with; The National Institute for Biological Standards and Control as well as the Centre of the Medicines and Healthcare products Regulatory Agency, in a joint effort to accelerate the development of advanced therapies in the UK.

This new collaboration plans to maximise and further promote scientific collaboration in the field of advanced therapies. This will look to develop the UK as a centre for research and manufacture in gene therapystem cell therapy and tissue engineering. 

A memorandum of understanding has been signed recognising the great promise such therapies hold in preventing and treating diseases such as Alzheimer’s, cancer or muscular dystrophy. As part of the agreement NIBSC and UCL will collaborate and share knowledge and resources to help support the development of safe and effective advanced therapies.

Advanced therapies such as stem cell treatments have huge potential in directly targeting and treating a range of conditions,” said Professor Mary Collins head of the Advanced Therapies unit at NIBS, noting that “closer working with University College London will greatly help to take forward studies that focus on therapeutic areas of gene and cell therapies”.

Advanced therapies, could help treat a huge range of different diseases that have little or no known possible treatments so a new collaboration that would enable a faster development of these treatments would be hugely beneficial for the medical world as well as further enhancing the reputation of the UK in the life sciences industry. This new announcement also begs to ask the question about the east of England’s bioscience boom and whether or not that the supposed golden triangle will stop growing?

Alex Carson

PiR Resourcing leaders in senior life science resourcing. For more news and information, you can follow us on Twitter and LinkedIn  For all our latest roles in the Life Science sector please click here.



Leave a Reply